Solid Biosciences (SLDB) Cash from Operations (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Cash from Operations data on file, last reported at 47230000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 48.29% year-over-year to 47230000.0; the trailing twelve-month figure through Mar 2026 stood at 171669000.0 (down 60.93% YoY), and the FY2025 full-year result was 156289000.0, down 56.27% from the prior year.
• Cash from Operations grew to 47230000.0 in Q1 2026, from 53555000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 15878000.0 in Q2 2022 to a low of 53555000.0 in Q4 2025.
• A 5-year average of 29158117.65 and a median of 27465000.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 39.61% in 2023 and slumped 80.65% in 2025, its largest moves.
• Tracing SLDB's Cash from Operations over 5 years: stood at 34480000.0 in 2022, then surged by 39.61% to 20823000.0 in 2023, then plunged by 42.37% to 29645000.0 in 2024, then sank by 80.65% to 53555000.0 in 2025, then gained by 11.81% to 47230000.0 in 2026.
• Business Quant data shows SLDB's Cash from Operations at 47230000.0 in Q1 2026, 53555000.0 in Q4 2025, and 33472000.0 in Q3 2025.